Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

PBI-4050 via GPR40 activation improves adenine-induced kidney injury in mice.

Thibodeau JF, Simard JC, Holterman CE, Blais A, Cloutier MP, Medeiros T, Leduc M, Grouix B, Leblond FA, Burger D, Hébert RL, Kennedy CRJ, Gagnon L.

Clin Sci (Lond). 2019 Jul 22;133(14):1587-1602. doi: 10.1042/CS20190479. Print 2019 Jul 31.

PMID:
31308217
2.

PBI-4050 Reduces Pulmonary Hypertension, Lung fibrosis and Right Ventricular Dysfunction in Heart Failure.

Nguyen QT, Jalloul Nsaibia M, Sirois MG, Calderone A, Tardif JC, Fen Shi Y, Ruiz M, Daneault C, Gagnon L, Grouix B, Laurin P, Dupuis J.

Cardiovasc Res. 2019 Feb 7. doi: 10.1093/cvr/cvz034. [Epub ahead of print]

PMID:
30753422
3.

Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation.

Zacharie B, Abbott SD, Duceppe JS, Gagnon L, Grouix B, Geerts L, Gervais L, Sarra-Bournet F, Perron V, Wilb N, Penney CL, Laurin P.

ChemistryOpen. 2018 Sep 21;7(9):737-749. doi: 10.1002/open.201800136. eCollection 2018 Sep.

4.

PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway.

Grouix B, Sarra-Bournet F, Leduc M, Simard JC, Hince K, Geerts L, Blais A, Gervais L, Laverdure A, Felton A, Richard J, Ouboudinar J, Gagnon W, Leblond FA, Laurin P, Gagnon L.

J Pharmacol Exp Ther. 2018 Oct;367(1):71-81. doi: 10.1124/jpet.118.250068. Epub 2018 Aug 9.

PMID:
30093459
5.

Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control.

Li Y, Chung S, Li Z, Overstreet JM, Gagnon L, Grouix B, Leduc M, Laurin P, Zhang MZ, Harris RC.

JCI Insight. 2018 May 17;3(10). pii: 120365. doi: 10.1172/jci.insight.120365. eCollection 2018 May 17.

6.

A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84.

Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, Gagnon W, Hince K, Tremblay M, Geerts L, Kennedy CRJ, Hébert RL, Gutsol A, Holterman CE, Kamto E, Gervais L, Ouboudinar J, Richard J, Felton A, Laverdure A, Simard JC, Létourneau S, Cloutier MP, Leblond FA, Abbott SD, Penney C, Duceppe JS, Zacharie B, Dupuis J, Calderone A, Nguyen QT, Harris RC, Laurin P.

Am J Pathol. 2018 May;188(5):1132-1148. doi: 10.1016/j.ajpath.2018.01.009. Epub 2018 Feb 16.

7.

2,4,6-trisubstituted triazines as protein a mimetics for the treatment of autoimmune diseases.

Zacharie B, Abbott SD, Bienvenu JF, Cameron AD, Cloutier J, Duceppe JS, Ezzitouni A, Fortin D, Houde K, Lauzon C, Moreau N, Perron V, Wilb N, Asselin M, Doucet A, Fafard ME, Gaudreau D, Grouix B, Sarra-Bournet F, St-Amant N, Gagnon L, Penney CL.

J Med Chem. 2010 Feb 11;53(3):1138-45. doi: 10.1021/jm901403r.

PMID:
20047277
8.

2,6,9-Trisubstituted purine derivatives as protein A mimetics for the treatment of autoimmune diseases.

Zacharie B, Fortin D, Wilb N, Bienvenu JF, Asselin M, Grouix B, Penney C.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):242-6. doi: 10.1016/j.bmcl.2008.10.116. Epub 2008 Oct 31.

PMID:
19010675
9.

A novel RGD antagonist that targets both alphavbeta3 and alpha5beta1 induces apoptosis of angiogenic endothelial cells on type I collagen.

Meerovitch K, Bergeron F, Leblond L, Grouix B, Poirier C, Bubenik M, Chan L, Gourdeau H, Bowlin T, Attardo G.

Vascul Pharmacol. 2003 Feb;40(2):77-89.

PMID:
12646396
10.

In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.

Leblond L, Grouix B, Boudreau C, Yang Q, Siddiqui MA, Winocour PD.

Thromb Res. 2000 Nov 1;100(3):195-209.

PMID:
11108907
11.

Coordinate expression of group II phospholipase A2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells.

Vadas P, Grouix B, Stefanski E, Wloch M, Pruzanski W, Schroeder J, Gauldie J.

Clin Exp Immunol. 1997 Apr;108(1):175-80.

12.

Secretory non-pancreatic phospholipase A2 and cyclooxygenase-2 expression by tracheobronchial smooth muscle cells.

Vadas P, Stefanski E, Wloch M, Grouix B, Van Den Bosch H, Kennedy B.

Eur J Biochem. 1996 Feb 1;235(3):557-63.

13.

Induction of release of secretory nonpancreatic phospholipase A2 from human articular chondrocytes.

Pruzanski W, Bogoch E, Katz A, Wloch M, Stefanski E, Grouix B, Sakotic G, Vadas P.

J Rheumatol. 1995 Nov;22(11):2114-9.

PMID:
8596153
14.
15.

Inhibition of human group II phospholipase A2 by C-reactive protein in vitro.

Vadas P, Stefanski E, Grouix B, Schouten BD, Pruzanski W.

J Lipid Mediat Cell Signal. 1995 Mar;11(2):187-200.

PMID:
7780685
16.

Clinical value of immunolymphscintigraphy in patients with breast cancer.

Schatten C, Pateisky N, Enzelsberger H, Grouix B, Mandeville R.

In Vivo. 1988 Sep-Oct;2(5):321-4.

PMID:
2979852
17.

Affinity purification of a high molecular weight human breast cancer-associated antigen identified by the BCD-B4 monoclonal antibody.

Mandeville R, Dumas F, Amarouch A, Sidrac-Ghali S, Walker MC, Zelechowska M, Ajdukovic I, Grouix B.

Hybridoma. 1987 Oct;6(5):441-51.

PMID:
3679257
18.

Immunolymphscintigraphy of axillary lymph node metastases in breast cancer patients using monoclonal antibodies: first clinical findings.

Mandeville R, Pateisky N, Philipp K, Kubista E, Dumas F, Grouix B.

Anticancer Res. 1986 Nov-Dec;6(6):1257-63.

PMID:
3813482
20.

Recognition and regulation by modified self.

Scott DW, Darrow TL, Grouix B, Wilson LA.

Ann N Y Acad Sci. 1982;392:1-8. No abstract available.

PMID:
6215875
21.

Serum thymic factor (FTS) restores the ability of adult thymectomized mice to be suppressed by hapten-modified self.

Grouix B, Charreire J, Erard D, Galanaud P, Bach JF.

Cell Immunol. 1981 Oct;64(1):144-9. No abstract available.

PMID:
6457694

Supplemental Content

Loading ...
Support Center